Dr. Agarwal's Health Care Limited has informed the Exchange about Investor Presentation
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Agarwal's Health Care reported strong Q1 FY26 results with consolidated total income of ₹501 Cr, up 22.3% YoY. IndAS EBITDA grew 28.9% to ₹141 Cr, with margins expanding from 26.8% to 28.2%. Profit After Tax more than doubled to ₹38 Cr (up 108.9% YoY), with PAT margins improving from 4.4% to 7.6%. The company served 705,214 patients and performed 78,882 surgeries, operating 249 eye care facilities (13 added this quarter). Management outlined plans to add 54 more facilities across the remaining three quarters, with South India being the focus (31 of 54 new centers). The company also turned into a net cash position of ₹278 Cr, with gross debt falling from ₹393 Cr to ₹175 Cr YoY.
Strong across-the-board growth in revenue, profits, and margins signals robust operational momentum. The shift to a net cash position strengthens the balance sheet, and the aggressive 54-facility expansion plan highlights confidence in sustained growth. Positive read for shareholders — likely to be viewed favorably by the market.